LAUREL EDINBURGH: Open Payments
NPI 1871552323 · MINNEAPOLIS, MN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,404 in 72 payments from 11 companies in 2025. Trend: 2023 $94 · 2024 $412 · 2025 $1,404
Food & beverage: $1,404
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $224 |
| ABBVIE INC. | 16 | $222 |
| Janssen Pharmaceuticals, Inc | 6 | $219 |
| Alkermes, Inc. | 11 | $172 |
| Vanda Pharmaceuticals Inc. | 6 | $148 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $136 |
| Teva Pharmaceuticals USA, Inc. | 6 | $113 |
| E.R. Squibb & Sons, L.L.C. | 3 | $66 |
| Lundbeck LLC | 3 | $59 |
| Braeburn Inc. | 1 | $24 |
Products named: REXULTI, INVEGA SUSTENNA, VRAYLAR, FANAPT, CAPLYTA, ARISTADA, AUSTEDO XR, COBENFY.
Industry payments across MN — which companies pay providers there.
